Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
Staff
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD – The Liver Meeting® 2024
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients Both artificial intelligence (AI) and...
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Epsom Salt Council Sponsors the Arthritis Foundation’s North Carolina Jingle Bell Runs to Benefit Critical Research Initiatives
The races will take place in Charlotte and Raleigh ahead of the holiday season CHARLOTTE, NC / ACCESSWIRE / November...
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
– sdATEVs maintained sustained patency throughout the six-month study – – sdATEV was observed to recellularize with host cells and...
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens...
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel...
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada’s Drug Agency and Quebec’s INESSS
LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC),...
genXtraits Inc. licenses Fulcrum™ toolkit from Pairwise to enable its technology platform for generation of high-value enhanced crops with dominant traits
ALAMEDA ISLAND, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- genXtraits Inc. (genXtraits) today announced that it has entered into an...
Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets
CHICAGO, IL / ACCESSWIRE / November 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing...
Interactive Strength Inc. (Nasdaq:TRNR) Expands CLMBR’s Presence with Military and College Accounts by Exhibiting at the Athletic Business Show on November 19-22
The Atheltic Business Show features Military and College/High School buyers, which represent some of the biggest customer segments in the...
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type...
Novonesis will host an educational conference call on Energy on December 18
Novonesis will host a spotlight educational session on our Energy activities which is part of Planetary Health Biosolutions. We will...
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations
LAS VEGAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- One World Products, Inc. (“OWP”) (OTCQB: OWPC), renowned for its innovative approach...
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with...
Incyclix Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate INX-315 in Combination with Verzenio® (abemaciclib) and Fulvestrant in HR+/HER2- Breast Cancer
INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant Combination therapy to be...
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D ProgramTORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE...